Full Press Release Details
Dalia R. Rayes has been our Head of Commercial, Global Efzofitimod Franchise since March 2025. Ms. Rayes has over two decades of experience building and leading commercial organizations at biotech and pharmaceutical companies, including leading rare disease product launches. From August 2023 to March 2025, Ms. Rayes served in an advisory capacity for several companies, including as a strategic advisor to aTyr from February 2024 to March 2025. Previously, from 2018 to 2022, she was Senior Vice President, Head of Commercial for ChemoCentryx, Inc., where she developed and implemented the commercial strategy for the launch of their first product TAVNEOS® ahead of their subsequent acquisition by Amgen. From 2005 to 2018, she worked for Actelion Pharmaceuticals Ltd., where she held key commercial leadership roles across several franchises ahead of their acquisition by Johnson & Johnson. As Senior Director, Business Unit Lead, she launched and scaled the rare disease franchise for VALCHLOR®, and earlier helped lead the blockbuster U.S. launch of OPSUMIT® within the pulmonary arterial hypertension (PAH) portfolio. Ms. Rayes began her career at Algorithm Pharmaceuticals, overseeing product launches across 13 countries in the Middle East and North Africa. Ms. Rayes holds an MBA from the Lebanese American University and a Bachelor of Science in Pharmacy from Beirut Arab University.